Published in J Steroid Biochem Mol Biol on March 10, 2008
Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res (2009) 1.37
Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2012) 1.19
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
Cholesterol 25-hydroxylation activity of CYP3A. J Lipid Res (2011) 1.11
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Diversity of bile salts in fish and amphibians: evolution of a complex biochemical pathway. Physiol Biochem Zool (2010) 1.04
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97
Intrinsic disorder in nuclear hormone receptors. J Proteome Res (2008) 0.92
An amphioxus orthologue of the estrogen receptor that does not bind estradiol: insights into estrogen receptor evolution. BMC Evol Biol (2008) 0.91
Retinoic acid actions through mammalian nuclear receptors. Chem Rev (2013) 0.90
The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem (2011) 0.89
Cholesterol efflux is LXRα isoform-dependent in human macrophages. BMC Cardiovasc Disord (2014) 0.85
Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database. Environ Health Perspect (2010) 0.80
Understanding nuclear receptors using computational methods. Drug Discov Today (2009) 0.80
LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. Am J Cancer Res (2013) 0.80
The tryptophan photoproduct 6-formylindolo[3,2-b]carbazole helps genes jump. Proc Natl Acad Sci U S A (2010) 0.78
Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J Gastroenterol (2012) 0.77
Cytochrome P450 20A1 in zebrafish: Cloning, regulation and potential involvement in hyperactivity disorders. Toxicol Appl Pharmacol (2016) 0.76
Ligand Similarity Complements Sequence, Physical Interaction, and Co-Expression for Gene Function Prediction. PLoS One (2016) 0.75
Evolutionary Origin of the Interferon-Immune Metabolic Axis: The Sterol-Vitamin D Link. Front Immunol (2017) 0.75
LXRα and LXRβ nuclear receptors evolved in the common ancestor of gnathostomes. Genome Biol Evol (2017) 0.75
Transcriptional changes in African clawed frogs (Xenopus laevis) exposed to 17α-ethynylestradiol during early development. Ecotoxicology (2014) 0.75
Role of Intestinal LXRα in Regulating Post-prandial Lipid Excursion and Diet-Induced Hypercholesterolemia and Hepatic Lipid Accumulation. Front Physiol (2017) 0.75
Chemical genetics and strigolactone perception. F1000Res (2017) 0.75
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
Tunicates and not cephalochordates are the closest living relatives of vertebrates. Nature (2006) 7.96
An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature (1996) 7.86
Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci (1998) 7.03
Role of LXRs in control of lipogenesis. Genes Dev (2000) 6.98
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A (1999) 5.08
Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem (1997) 4.81
Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. Cell (2006) 3.82
LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol (2006) 3.11
Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science (2003) 2.49
Genetic analysis of digestive physiology using fluorescent phospholipid reporters. Science (2001) 2.36
Optimizing long intrinsic disorder predictors with protein evolutionary information. J Bioinform Comput Biol (2005) 2.20
Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem (2002) 2.01
Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc Natl Acad Sci U S A (1994) 1.69
The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev Biol (2006) 1.54
Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances. J Biol Chem (1987) 1.53
High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res (1987) 1.51
A more detailed study of bile salt evolution, including techniques for small-scale identification and their application to amphibian biles. Biochem J (1974) 1.48
Binding of ligands and activation of transcription by nuclear receptors. Annu Rev Biophys Biomol Struct (2001) 1.46
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J Biol Chem (2003) 1.33
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33
Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J (2003) 1.31
Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology (2000) 1.28
The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Res (2003) 1.20
Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept (2005) 1.17
A chemoattractant for ascidian spermatozoa is a sulfated steroid. Proc Natl Acad Sci U S A (2002) 1.13
A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm Res (2002) 1.10
A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res (2005) 1.08
The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J Biol Chem (2003) 1.01
Physicochemical and physiological properties of 5alpha-cyprinol sulfate, the toxic bile salt of cyprinid fish. J Lipid Res (2003) 0.99
A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther (2003) 0.98
A genomewide survey of developmentally relevant genes in Ciona intestinalis. III. Genes for Fox, ETS, nuclear receptors and NFkappaB. Dev Genes Evol (2003) 0.98
Natural occurrence and chemical synthesis of bile alcohols, higher bile acids, and short side chain bile acids. Hiroshima J Med Sci (1994) 0.96
Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids (2000) 0.93
FOR, a novel orphan nuclear receptor related to farnesoid X receptor. J Biol Chem (2002) 0.93
Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. J Med Chem (2005) 0.91
Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J Mol Biol (2003) 0.90
Oxysterol nuclear receptor LXRbeta regulates cholesterol homeostasis and contractile function in mouse uterus. J Biol Chem (2006) 0.85
Identification and biosynthesis of steroid hormones in the gonads of Ciona intestinalis. Experientia (1971) 0.80
On the sterols of some ascidians. Arch Int Physiol Biochim (1975) 0.80
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Educating medical students in laboratory medicine: a proposed curriculum. Am J Clin Pathol (2010) 3.18
Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect (2004) 2.16
Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect (2012) 1.81
Lack of androgenicity and estrogenicity of the three monomers used in Eastman's Tritan™ copolyesters. Food Chem Toxicol (2012) 1.76
A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett (2005) 1.71
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des (2011) 1.68
Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology (2003) 1.51
Gaussian mixture clustering and imputation of microarray data. Bioinformatics (2004) 1.49
In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today (2011) 1.45
Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 1.40
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem (2003) 1.39
Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today (2012) 1.39
POSITIVE TEST FOR ANTITHYROGLOBULIN ANTIBODIES DUE TO ADMINISTRATION OF IMMUNOGLOBULIN REPLACEMENT THERAPY IN A PATIENT WITH THYROID CANCER. Endocr Pract (2015) 1.38
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res (2009) 1.37
Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol (2007) 1.35
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33
Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab (2006) 1.32
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology (2010) 1.26
Mobile apps for chemistry in the world of drug discovery. Drug Discov Today (2011) 1.26
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
Methods for predicting human drug metabolism. Adv Clin Chem (2007) 1.24
DNA microarray data imputation and significance analysis of differential expression. Bioinformatics (2005) 1.24
A quality alert and call for improved curation of public chemistry databases. Drug Discov Today (2011) 1.22
Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr (2008) 1.21
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol (2007) 1.17
Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept (2005) 1.17
A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
Reaching out to collaborators: crowdsourcing for pharmaceutical research. Pharm Res (2010) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem (2007) 1.13
Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12
Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem. BMC Clin Pathol (2012) 1.11
A "forward genomics" approach links genotype to phenotype using independent phenotypic losses among related species. Cell Rep (2012) 1.10
Improved method for predicting beta-turn using support vector machine. Bioinformatics (2005) 1.10
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Accurate enzymatic measurement of fecal bile acids in patients with malabsorption. J Lab Clin Med (2003) 1.09
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem (2010) 1.09
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol (2003) 1.08
A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res (2005) 1.08
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today (2013) 1.07
Detection of Δ4-3-oxo-steroid 5β-reductase deficiency by LC-ESI-MS/MS measurement of urinary bile acids. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 1.05
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today (2012) 1.05
Diversity of bile salts in fish and amphibians: evolution of a complex biochemical pathway. Physiol Biochem Zool (2010) 1.04
Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2009) 1.04
Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos (2010) 1.04
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Time for cooperation in health economics among the modelling community. Pharmacoeconomics (2010) 1.04
Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today (2006) 1.03
Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem (2003) 1.03
Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res (2005) 1.03
Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Using surrogate modeling in the prediction of fibrinogen adsorption onto polymer surfaces. J Chem Inf Comput Sci (2004) 1.00
Enrichment of ligands for the serotonin receptor using the Shape Signatures approach. J Chem Inf Model (2005) 1.00
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers (2003) 0.99
Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. J Chem Inf Model (2010) 0.99
Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: Structure-activity relationships. Am J Physiol Gastrointest Liver Physiol (2006) 0.99
Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol (2008) 0.98
Prediction of the orientations of adsorbed protein using an empirical energy function with implicit solvation. Langmuir (2005) 0.98
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas. Proc Natl Acad Sci U S A (2007) 0.98
Wavelet analysis of DNA walks. J Comput Biol (2006) 0.98
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97